GSK 1995057

Drug Profile

GSK 1995057

Alternative Names: GSK1995057

Latest Information Update: 02 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antibodies
  • Mechanism of Action Type 1 tumour necrosis factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute lung injury; Adult respiratory distress syndrome

Most Recent Events

  • 30 Sep 2012 GlaxoSmithKline completes a phase I trial in Healthy volunteers in United Kingdom (NCT01587807)
  • 30 Apr 2012 GlaxoSmithKline completes a phase I trial in Healthy volunteers in United Kingdom (NCT01476046)
  • 31 Mar 2012 Phase-I clinical trials in Acute lung injury in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top